{
    "accountDetails": {
        "accountHasCodexViolations": false,
        "activeDateRanges": [
            {
                "fromDate": "2022-09-15T09:58:36.000+02:00",
                "untilDate": "2024-07-02T00:11:32.000+02:00"
            }
        ],
        "firstPublicationDate": "2022-09-15T09:58:36.000+02:00",
        "inactiveDateRanges": [
            {
                "fromDate": "2024-07-02T00:11:32.000+02:00"
            }
        ],
        "lastUpdateDate": "2023-09-22T09:29:20.000+02:00",
        "registerEntryVersions": [
            {
                "activeUntilDate": "2024-07-02T00:11:32.000+02:00",
                "legislation": "GL2022",
                "registerEntryId": 25098,
                "validFromDate": "2023-09-22T09:29:20.000+02:00",
                "version": 2,
                "versionActiveLobbyist": false
            },
            {
                "legislation": "GL2022",
                "registerEntryId": 11172,
                "validFromDate": "2022-09-15T09:58:36.000+02:00",
                "validUntilDate": "2023-09-22T09:29:20.000+02:00",
                "version": 1,
                "versionActiveLobbyist": true
            }
        ]
    },
    "activeLobbyist": false,
    "activitiesAndInterests": {
        "activity": {
            "code": "ACT_ORGANIZATION",
            "de": "Unternehmen",
            "en": "Company"
        },
        "activityDescription": "Amylyx ist ein junges pharmazeutisches Unternehmen, das es sich zur Aufgabe gemacht hat, Therapien f\u00fcr neurodegenerative Erkrankungen zu entwickeln und das Leiden Betroffener m\u00f6glichst zu beenden. Seit der Gr\u00fcndung 2013 in den USA widmet sich Amylyx zun\u00e4chst der Krankheit Amyotrophe Lateralskelrose, kurz ALS.\r\nIn Deutschland begleitet Amylyx Pharmaceuticals Germany GmbH legislative und politische Initiativen mit dem Ziel, die Rahmenbedingungen f\u00fcr Patienten mit seltenen Erkrankungen zu verbessern.",
        "activityOperationType": "BOTH",
        "fieldsOfInterest": [
            {
                "code": "FOI_HEALTH",
                "de": "Gesundheit",
                "en": "Health"
            },
            {
                "code": "FOI_HEALTH_MEDICINE",
                "de": "Arzneimittel",
                "en": "Medicine"
            },
            {
                "code": "FOI_SCIENCE_RESEARCH_TECHNOLOGY",
                "de": "Wissenschaft, Forschung und Technologie",
                "en": "Science, research and technology"
            },
            {
                "code": "FOI_HEALTH_SUPPLY",
                "de": "Gesundheitsversorgung",
                "en": "Health supply"
            }
        ],
        "legislativeProjects": []
    },
    "annualReports": {
        "annualReportExists": false,
        "disclosureRequirementsExist": true,
        "missingAnnualReportReason": "Das Unternehmen wurde erst in 2022 gegr\u00fcndet."
    },
    "clientIdentity": {
        "clientsPresent": false
    },
    "codeOfConduct": {
        "ownCodeOfConduct": false
    },
    "donators": {
        "fiscalYearCompleted": false,
        "refuseDonatorsInformation": false
    },
    "employeesInvolvedInLobbying": {
        "employeesCount": {
            "from": 1,
            "to": 10
        }
    },
    "financialExpenses": {
        "fiscalYearCompleted": false,
        "refuseFinancialExpensesInformation": false
    },
    "legislation": "GL2022",
    "lobbyistIdentity": {
        "address": {
            "city": "M\u00fcnchen",
            "country": {
                "code": "DE",
                "de": "Deutschland",
                "en": "Germany"
            },
            "nationalAdditional1": "Amylyx Pharma. Germany GmbH",
            "street": "Karl-Scharnagl-Ring",
            "streetNumber": "5",
            "type": "NATIONAL",
            "zipCode": "80539"
        },
        "contactDetails": {
            "emails": [
                {
                    "email": "susanne_digel@amylyx.com"
                }
            ],
            "phoneNumber": "+31203698199",
            "websites": [
                {
                    "website": "www.amylyx.com"
                }
            ]
        },
        "identity": "ORGANIZATION",
        "legalForm": {
            "code": "LF_GMBH",
            "de": "Gesellschaft mit beschr\u00e4nkter Haftung (GmbH)",
            "en": "Limited liability company (GmbH)"
        },
        "legalFormType": {
            "code": "JURISTIC_PERSON",
            "de": "Juristische Person",
            "en": "Legal person"
        },
        "legalRepresentatives": [
            {
                "commonFirstName": "St\u00e9phanie",
                "emails": [
                    {
                        "email": "stephanie_hoffmann@amylyx.com"
                    }
                ],
                "function": "Head EMEA",
                "lastName": "Hoffmann",
                "phoneNumber": "+31203698199"
            },
            {
                "commonFirstName": "Thomas",
                "emails": [
                    {
                        "email": "thomas_biet@amylyx.com"
                    }
                ],
                "function": "Head EMEA Finance",
                "lastName": "Biet",
                "phoneNumber": "+31203698199"
            },
            {
                "commonFirstName": "Susanne",
                "emails": [
                    {
                        "email": "susanne_digel@amylyx.com"
                    }
                ],
                "function": "General Manager",
                "lastName": "Digel",
                "phoneNumber": "+31203698199"
            }
        ],
        "membersPresent": false,
        "membershipsPresent": false,
        "name": "Amylyx Pharmaceuticals Germany GmbH",
        "namedEmployees": [
            {
                "academicDegreeBefore": "Doktor",
                "commonFirstName": "Colin",
                "lastName": "Wernsd\u00f6rfer"
            },
            {
                "commonFirstName": "Susanne",
                "lastName": "Digel"
            }
        ],
        "namedEmployeesPresent": true
    },
    "publicAllowances": {
        "fiscalYearCompleted": false,
        "refusePublicAllowancesInformation": false
    },
    "registerEntryDetails": {
        "annualUpdate": {
            "lastAnnualUpdate": "2023-09-22T09:29:20.000+02:00",
            "updateMissing": false
        },
        "detailsPageUrl": "https://www.lobbyregister.bundestag.de/suche/R005201/25098",
        "pdfUrl": "https://www.lobbyregister.bundestag.de/media/c1/38/233013/Lobbyregister-Detailansicht-R005201-2023-09-22_09-29-20.pdf",
        "refusedAnything": false,
        "validFromDate": "2023-09-22T09:29:20.000+02:00",
        "version": 2
    },
    "registerEntryId": 25098,
    "registerNumber": "R005201"
}